Diffuse large B-cell lymphoma (DLBCL) represents approximately 24% of all new B-cell non-Hodgkin lymphoma diagnoses each year in the United States. The Standard of treatment is normally, “rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone; however, 30-40% of patients experience relapsed or refractory (R/R) disease.”
High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) can improve outcomes for patients with R/R disease. However, many patients are ineligible for either treatment, leaving patients with few options to battle this disease.
Tafasitamab-cxix (Monjuvi) in combination with lenalidomide is a promising new treatment for adult patients with R/R DLBCL.
This medication combination is administered intravenously. It may lower some types of blood cells in your body resulting in frequent bleeding and infections. Other common side effects, which may resolve during treatment, are:
“Patients received coadministered intravenous tafasitamab (12 mg/kg) and oral lenalidomide (25 mg/day) for up to 12 cycles (28 days each), followed by tafasitamab monotherapy (in patients with stable disease or better) until disease progression.”
The combination of tafasitamab and lenalidomide has shown to be an effective treatment option for patients who are transplant ineligible and have relapsed or refractory disease 12 months after first-line therapy.
Diffuse large B-cell lymphoma (DLBCL) represents approximately 24% of all new B-cell non-Hodgkin lymphoma diagnoses each year in the United States. The Standard of treatment is normally, “rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone; however, 30-40% of patients experience relapsed or refractory (R/R) disease.”
High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) can improve outcomes for patients with R/R disease. However, many patients are ineligible for either treatment, leaving patients with few options to battle this disease.
Tafasitamab-cxix (Monjuvi) in combination with lenalidomide is a promising new treatment for adult patients with R/R DLBCL.
This medication combination is administered intravenously. It may lower some types of blood cells in your body resulting in frequent bleeding and infections. Other common side effects, which may resolve during treatment, are:
“Patients received coadministered intravenous tafasitamab (12 mg/kg) and oral lenalidomide (25 mg/day) for up to 12 cycles (28 days each), followed by tafasitamab monotherapy (in patients with stable disease or better) until disease progression.”
The combination of tafasitamab and lenalidomide has shown to be an effective treatment option for patients who are transplant ineligible and have relapsed or refractory disease 12 months after first-line therapy.
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, a writer, and a HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.